ALS Clinical Trials in New York

Showing 61-79 of 79 trials

First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis

NCT00875446

The drug being tested in this study is GSK1223249. It is being developed by GlaxoSmithKline to treat symptoms in patients with Amyotrophic Lateral Sclerosis (ALS). The drug works by inhibiting the protein that prevents nerve growth. This will be the first time the drug will be given to man. The trial is expected to involve approximately 76 patients. The study objective is to investigate the tolerability, safety and the way the body handles GSK1223249 after a range of single doses or repeat dose escalation in patients with ALS.

Amyotrophic Lateral Sclerosis

GlaxoSmithKline76 participantsStarted May 2009

Baltimore, Maryland, United States • New York, New York, United States • Syracuse, New York, United States +9 more locations

COMPLETEDPhase 1< 1 mile

Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy

NCT02494024

This study will evaluate the safety and tolerability (maximum tolerated dose (MTD) within the specified dosing range) of single intravenous (IV) infusion of C2N-8E12 in patients with progressive supranuclear palsy (PSP).

Progressive Supranuclear Palsy

C2N Diagnostics32 participantsStarted Jul 2015

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Los Angeles, California, United States +9 more locations

PreviousPage 4 of 4

First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis

Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy

ALS Trials in Other Cities

SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)

Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy

Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS

Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS

Talampanel for Amyotrophic Lateral Sclerosis (ALS)

Minocycline to Treat Amyotrophic Lateral Sclerosis

Study Assessing High-Frequency Chest Wall Oscillation (HFCWO) in Preventing Pulmonary Exacerbations

The Effect of Combined Armeospring and CIT on Neuro-motor and Functional Recovery in Children With Unilateral CP

Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)

Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls

A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS

Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)

Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS)

Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS)

Study of Electrical Impedance Myography (EIM) in ALS

Other Conditions in New York